ReviewImmune network2016
The Immune Landscape in Nonalcoholic Steatohepatitis.
Review in Immune network, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis.Frontiers in aging neuroscience · 2022Pooled it
- Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.Diabetes & metabolic syndromePooled it
- Review
- Article
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.Gastroenterology report · 2024Review
- Chest CT opportunistic biomarkers for phenotyping high-risk COVID-19 patients: a retrospective multicentre study.European radiology · 2023Article
- A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response.Nutrition & metabolism · 2023Article
- Advances in human organoids-on-chips in biomedical research.Life medicine · 2023Review
- Targeting macrophagic 17Acta pharmaceutica Sinica. B · 2023Article
- Understanding the cellular interactome of non-alcoholic fatty liver disease.JHEP reports : innovation in hepatology · 2022Review
- Review
- Pathogenesis from Inflammation to Cancer in NASH-Derived HCC.Journal of hepatocellular carcinoma · 2022Review
- The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis.Kansas journal of medicine · 2022Article
- Liver Injury and Elevated FIB-4 Define a High-Risk Group in Patients with COVID-19.Journal of clinical medicine · 2021Article
- Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China.BMC gastroenterology · 2021Article
- T Cell Subsets and Natural Killer Cells in the Pathogenesis of Nonalcoholic Fatty Liver Disease.International journal of molecular sciences · 2021Review
- COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence.Journal of clinical and translational hepatology · 2021Review
- Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence.World journal of hepatology · 2021Review
- Relationship between NAFLD and Periodontal Disease from the View of Clinical and Basic Research, and Immunological Response.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The liver lies at the intersection of multiple metabolic pathways and consequently plays a central role in lipid metabolism. Pathological disturbances in hepatic lipid metabolism are characteristic of chronic metabolic diseases, such as obesity-mediated insulin resistance, which can result in nonalcoholic fatty liver disease (NAFLD). Tissue damage induced in NAFLD activates and recruits liver-resident and non-resident immune cells, resulting in nonalcoholic steatohepatitis (NASH). Importantly, NASH is associated with an increased risk of significant clinical sequelae such as cirrhosis, cardiovascular diseases, and malignancies. In this review, we describe the immunopathogenesis of NASH by defining the known functions of immune cells in the progression and resolution of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.